Kura Oncology, Inc.
Close on Oct 19, 2026
- Market cap
- $831.68M
- P/E (TTM)
- –
- Dividend yield
- –
About Kura Oncology
Pharmaceutical Preparations, SIC 2834
Kura Oncology, Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes precision medicines for the treatment of cancer. The company focuses on small-molecule drug candidates that target cancer signaling pathways to address unmet needs in oncology and hematology. Its approved product is KOMZIFTI (ziftomenib), an oral menin inhibitor administered once daily. The company also advances drug candidates across clinical trials, including evaluation in combination therapies for acute myeloid leukemia. Its therapies primarily serve adult cancer patients, particularly those diagnosed with relapsed or refractory acute myeloid leukemia harboring susceptible nucleophosmin 1 mutations.
The company conducts its business and clinical operations within the United States and collaborates with global partners, including Kyowa Kirin. Its activities include regulatory development, research, and commercial distribution of its oncology therapies. Kura Oncology is headquartered in San Diego, California.
Summary of the business section of Kura Oncology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Kura Oncology, Inc.
- Founded
- 2014
- Headquarters
- San Diego, CA
- Address
- 4930 Directors Place, Suite 500 92121
- Phone
- (858) 500-8800
- Website
- www.kuraoncology.com
- Employees
- 260, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, CA USA
Stock & identifiers
- Ticker
- KURA
- Exchange
- Nasdaq
- IPO date
- Sep 16, 2015
- Shares outstanding
- 89M, Aug 7, 2026
- Public float
- $496.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1422143
- CUSIP
- 50127T109
- ISIN
- US50127T1097
- LEI
- 5493005QORQTZCZYOP39
- EIN
- 61-1547851
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Troy Edward Wilson | President and CEO, Director | 1,214,650 |
| Thomas James Doyle | SVP, Finance & Accounting | 142,928 |
| Kathleen Ford | Chief Operating Officer | 142,986 |
| Brian T. Powl | Chief Commercial Officer | 136,819 |
| Teresa Brophy Bair | Chief Legal Officer | 187,002 |
| Mollie Leoni | Chief Medical Officer | 141,095 |
| Francis Burrows | Chief Scientific Officer | 63,053 |
| Jennifer Fulk | Chief Financial Officer | – |
| Helen Louise Collins | Director | – |
| Diane L. Parks | Director | – |
| Faheem Hasnain | Director | 23,983 |
| Mary T. Szela | Director | – |
| Thomas Malley | Director | 149,557 |
| Michael Vasconcelles | Director | – |
| Carol Schafer | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Troy E. Wilson, Ph.D., J.D | $4.74M | $6.49M | $2.29M | $84 | – |
| FY2024 Troy E. Wilson, Ph.D., J.D | $6.24M | $4.23M | $2.43M | $70 | – |
| FY2023 Troy E. Wilson, Ph.D., J.D | $5.25M | $5.95M | $2.20M | $116 | – |
| FY2022 Troy E. Wilson, Ph.D., J.D | $5.30M | $3.95M | $2.54M | $90 | $114 |
| FY2021 Troy E. Wilson, Ph.D., J.D | $8.74M | -$3.56M | $3.56M | $102 | $126 |
| FY2020 Troy E. Wilson, Ph.D., J.D | $4.19M | $13.89M | $2.26M | $238 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 260 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 4, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 12, 2015 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 12, 2015 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 10, 2015 | Name change | Name changed from ZETA ACQUISITION CORP III to Kura Oncology, Inc. |